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Background: IDO1 is key a heme-enzyme expressed by the human placenta. Through 
depletion of oxygen and tryptophan and kynuerenine production, it reduces 
proliferation and activity of T cells avoiding maternal-placental “rejection”. 
Moreover, IDO1 plays a role in reactive oxygen species management and it is 
inversely correlated to oxidative stress (OxS). 
Preeclampsia (PE) is a placenta-related syndrome characterized by abnormal 
maternal immune-response leading to aberrant placenta development and oxidative 
stress. According to the maternal/placental immune-maladaptation model, a role 
for IDO1 in PE pathogenesis has been hypothesized but never accurately 
demonstrated. 
 
Herein, we characterized IDO1 placental oxygen-mediated regulation and its 
expression in PE and CKD placentae, clinically indistinguishable from PE despite a 
different etiology and no placental compromise. 
Methods: Human term placental villous explants (n = 21) were cultured for 12h at 
20%pO2. Next, explants were treated oxygen-filled nanobubbles (OLNs-500 ul) and 
incubated in hypoxic conditions (3%pO2) or standard conditions (20%pO2) for 8 h. 
Untreated explants at 3%/20%pO2 were used as controls. Physiological (n = 15), PE 
(n = 15) and CKD (n = 21) placentae were collected. Placental biopsies and explants 
were processed for mRNA isolation. IDO1 mRNA levels were determined by Real 
Time PCR. 
Results: IDO1 mRNA levels were significantly increased in 20%pO2+OLNs (p<0.05, 
8.3 Fold Increase; OxS condition) and 3%pO2 (p<0.05, 4.6 Fold Increase) explants vs 
20%pO2 controls. Interestingly, 3%pO2+OLNs explants showed a reduction of IDO1 
mRNA levels (p<0.05, 2.0 Fold decrease) vs 3%pO2 controls. IDO1 expression was 
significantly reduced in PE compared to both CKD and control placentae (p < 0.05). 
Conclusions: In the present study, we demonstrated, for the first time to our 
knowledge, IDO1 oxygen-mediated expression in the human placenta. IDO1 down-
regulation further contributes to the pathological OxS environment typical of PE 
placentae. CKD placentae showed normal IDO1 expression, underlying a 
physiological placental environment. 
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